[go: up one dir, main page]

AU2001278003A1 - Bacteriophage having multiple host range - Google Patents

Bacteriophage having multiple host range

Info

Publication number
AU2001278003A1
AU2001278003A1 AU2001278003A AU7800301A AU2001278003A1 AU 2001278003 A1 AU2001278003 A1 AU 2001278003A1 AU 2001278003 A AU2001278003 A AU 2001278003A AU 7800301 A AU7800301 A AU 7800301A AU 2001278003 A1 AU2001278003 A1 AU 2001278003A1
Authority
AU
Australia
Prior art keywords
bacteriophage
host range
multiple host
prophylaxis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001278003A
Other languages
English (en)
Inventor
Sankar Adhya
Carl R. Merril
Deal Scholl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU2001278003A1 publication Critical patent/AU2001278003A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14211—Microviridae
    • C12N2795/14232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Toys (AREA)
  • Feedback Control In General (AREA)
AU2001278003A 2000-07-25 2001-07-25 Bacteriophage having multiple host range Abandoned AU2001278003A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22098700P 2000-07-25 2000-07-25
US60/220,987 2000-07-25
PCT/US2001/023390 WO2002007742A2 (fr) 2000-07-25 2001-07-25 Bacteriophage a spectre d'activite multiple

Publications (1)

Publication Number Publication Date
AU2001278003A1 true AU2001278003A1 (en) 2002-02-05

Family

ID=22825862

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001278003A Abandoned AU2001278003A1 (en) 2000-07-25 2001-07-25 Bacteriophage having multiple host range

Country Status (8)

Country Link
US (1) US7163818B2 (fr)
EP (1) EP1305038B1 (fr)
AT (1) ATE305793T1 (fr)
AU (1) AU2001278003A1 (fr)
CA (1) CA2417188A1 (fr)
DE (1) DE60113851T2 (fr)
ES (1) ES2252263T3 (fr)
WO (1) WO2002007742A2 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039111A1 (fr) * 1996-04-15 1997-10-23 Nymox Corporation Compositions contenant des bacteriophages et procedes d'utilisation des bacteriophages dans le traitement des infections
EP1267192B1 (fr) 2001-06-15 2009-02-18 Prysmian Cables & Systems Limited Connecter des fibres optiques
ES2283581T3 (es) * 2001-07-18 2007-11-01 Instytut Immunologii I Terapii Doswiadczalnej-Pan Procedimientos de preparacion de bacteriofagos polivalentes para el tratamiento de infeccines bascterianas.
GB0209680D0 (en) * 2002-04-27 2002-06-05 Univ Strathclyde Immobilisation and stabilisation of bacteriophage
US7588929B2 (en) 2002-12-09 2009-09-15 Phage Biopharm Llc Production of bacteriophage compositions for use in phage therapy
GB0300597D0 (en) 2003-01-10 2003-02-12 Microbiological Res Authority Phage biofilms
US7951579B2 (en) * 2003-04-07 2011-05-31 Board of Trutees of the University of Arkansas Method for bacteriophage delivery and amplification
EP2570130B1 (fr) 2003-07-23 2014-11-26 Biocontrol Limited Agents thérapeutiques contenant des bactériophages contre P. aeruginosa
GB0320838D0 (en) 2003-09-05 2003-10-08 Univ Nottingham Disinfection of foodstuffs
CA2593992A1 (fr) * 2004-12-06 2006-06-15 Rodney M. Donlan Inhibition de la formation de biofilm par un bacteriophage
WO2006066224A2 (fr) * 2004-12-14 2006-06-22 Yale University Antibiotiques ciblés contre un facteur de virulence
CA2775655C (fr) * 2005-01-20 2014-03-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Analyse multiplexee pour l'etablissement d'un serodiagnostic d'une infection virale
EP1855723B1 (fr) * 2005-03-08 2013-05-22 Ramot at Tel-Aviv University Ltd. Bacteriophages transportant des medicaments cibles
AU2006268420B2 (en) 2005-07-12 2012-06-28 Micreos B.V. Bacteriophage and their uses
US20090053179A1 (en) * 2005-10-05 2009-02-26 Internalle, Inc. Method for using liberated dormant bacteriophage and environmental stress to reduce infectious bacteria
US8178087B2 (en) 2006-04-04 2012-05-15 Centre National de la Recherche Scientifique —CNRS Process of production of bacteriophage compositions and methods in phage therapy field
KR100781669B1 (ko) * 2006-06-20 2007-12-03 주식회사 인트론바이오테크놀로지 황색포도상구균 특이적 사멸능을 갖는 박테리오파지
KR100759988B1 (ko) * 2006-08-04 2007-09-19 주식회사 인트론바이오테크놀로지 황색포도상구균에 특이적인 항균 단백질
FR2910493B1 (fr) * 2006-12-20 2012-12-14 Bio Modeling Systems Ou Bmsystems Procede de diversification aleatoire d'une sequence genetique permettant de preserver l'identite de certains segments internes de ladite sequence genetique
FR2910492B1 (fr) * 2006-12-20 2013-02-15 Bio Modeling Systems Ou Bmsystems Procede de preparation de bacteriophages modifies par insertion de sequences aleatoires dans les proteines de ciblage desdits bacteriophages
GB0704553D0 (en) 2007-03-09 2007-04-18 Harper David R Beneficial effects of bacteriophage treatments
WO2008121830A2 (fr) * 2007-03-30 2008-10-09 National Research Council Of Canada Protéines se liant à des récepteurs phagiques pour bactériothérapie et autres nouvelles utilisations
KR100910961B1 (ko) * 2007-09-13 2009-08-05 주식회사 인트론바이오테크놀로지 황색포도상구균의 균막 처치에 효과적인 박테리오파지 또는그것 유래의 용균단백질
US20100092431A1 (en) * 2008-05-15 2010-04-15 Auburn University Edwardsiella Ictaluri Bacteriophage and Uses Thereof
US8377866B2 (en) * 2009-02-12 2013-02-19 Intron Biotechnology, Inc. Antimicrobial protein derived from Podoviridae bacteriophage specific to Staphylococcus aureus
TWI458734B (zh) * 2011-04-20 2014-11-01 Univ Nat Taiwan 對克雷伯氏肺炎桿菌（ｋｌｅｂｓｉｅｌｌａ ｐｎｅｕｍｏｎｉａｅ）莢膜型菌株具專一性的新穎多肽及噬菌體及其應用
WO2013010660A1 (fr) * 2011-07-15 2013-01-24 Medizinische Hochschule Hannover (Mhh) Enzymes ayant une activité alpha-2,9-endosialidase
RU2518303C2 (ru) * 2012-06-29 2014-06-10 Федеральное бюджетное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии имени Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН МНИИЭМ им. Г.Н. Габричевского Роспотребнадзора) КОМПОЗИЦИЯ АНТИБАКТЕРИАЛЬНАЯ, ШТАММ БАКТЕРИОФАГА Escherichia coli, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ ТАКОЙ КОМПОЗИЦИИ.
US9617522B2 (en) 2013-09-05 2017-04-11 Massachusetts Institute Of Technology Tuning bacteriophage host range
EP2893933A1 (fr) * 2014-01-10 2015-07-15 Pherecydes Pharma Thérapie bactériophage des infections d'E. coli
GB201417811D0 (en) * 2014-10-08 2014-11-19 Phico Therapeutics Ltd Modifying bacteriophage
GB201417808D0 (en) 2014-10-08 2014-11-19 Phico Therapeutics Ltd Modified bacteriophage
GB201417810D0 (en) 2014-10-08 2014-11-19 Phico Therapeutics Ltd Modifying bacteriophage
GB201417805D0 (en) * 2014-10-08 2014-11-19 Phico Therapeutics Ltd Modifield bacteriophage
EP3018201A1 (fr) 2014-11-07 2016-05-11 Pherecydes Pharma Thérapie phagique
CN107278227B (zh) 2014-12-16 2021-05-28 C3J治疗公司 用于体外病毒基因组工程的组合物和方法
JP7166244B2 (ja) 2016-04-08 2022-11-07 フィコ セラピューティクス リミテッド 改変バクテリオファージ
ES2867029T3 (es) 2016-04-08 2021-10-20 Phico Therapeutics Ltd Bacteriófago modificado
EP3532850A1 (fr) 2016-10-28 2019-09-04 Massachusetts Institute Of Technology Bactériophages synthétiques et compositions bactériophages
KR101822812B1 (ko) * 2017-02-22 2018-01-29 주식회사 인트론바이오테크놀로지 신규한 엔테로코쿠스 패슘 박테리오파지 Ent-FAP-4 및 이의 엔테로코쿠스 패슘 증식 억제 용도
US10174295B1 (en) * 2017-08-01 2019-01-08 The Charles Stark Draper Laboratory, Inc. Composition of matter: engineering of Escherichia coli phage K1E
GB201712733D0 (en) 2017-08-08 2017-09-20 Snipr Tech Ltd Methods & cells
CA3088786A1 (fr) * 2018-01-19 2019-07-25 Cytophage Technologies Inc. Bacteriophage genetiquement modifie
GB201901099D0 (en) 2019-01-27 2019-03-13 Snipr Biome Aps Methods, uses and compositions
JP2022542023A (ja) * 2019-07-18 2022-09-29 テクニシェ ユニバーシタット ミュンヘン バクテリオファージの宿主に依存しない発現
CN112695017B (zh) * 2019-10-23 2022-04-15 吉林大学 噬菌体vB_Yen_X1及在防治鼠疫杆菌感染中应用
US11584781B2 (en) 2019-12-30 2023-02-21 Eligo Bioscience Chimeric receptor binding proteins resistant to proteolytic degradation
CN111876400B (zh) * 2020-08-06 2022-05-24 昆明理工大学 一种常温裂解酶Sly和编码此酶的多核苷酸
CN112143747B (zh) * 2020-09-09 2022-09-13 昆明理工大学 一种噬菌体裂解酶及其基因、基因重组表达载体与应用
CN113215114A (zh) * 2021-06-09 2021-08-06 西南石油大学 一种ndm-1大肠杆菌噬菌体及其分离方法和应用
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
WO2024003301A1 (fr) 2022-06-29 2024-01-04 Snipr Biome Aps Ciblage de cellules d'e. coli
EP4621049A1 (fr) * 2024-03-19 2025-09-24 Invitris GmbH Particules multispécifiques

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405720A (en) * 1981-03-04 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services Silver stains for protein in gels
US4508820A (en) * 1982-08-13 1985-04-02 The United States Of America As Represented By The Department Of Health And Human Services Method for simultaneously monitoring turnover rate in multiple proteins
US4555490A (en) * 1984-06-08 1985-11-26 The United States Of America As Represented By The Department Of Health And Human Services Rapid visualization system for gel electrophoresis
US4703016A (en) * 1986-05-05 1987-10-27 The United States Of America As Represented By The Department Of Health And Human Services Silver stain for rapid, quantitative detection of polypeptides and nucleic acids
US4940659A (en) * 1987-02-20 1990-07-10 Monoclonetics International, Inc. Screening extra-cellular body fluids for superoxide dismutase (SOD-1) for determining fetal trisomy 21 down syndrome
US4892814A (en) * 1987-06-22 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Method for distinguishing Creutzfeldt-Jakob disease from other dementias
US5817797A (en) * 1988-06-01 1998-10-06 The United States Of America As Represented By The Department Of Health And Human Services Sequencing DNA; a modification of the polymerase chain reaction
US5292665A (en) * 1989-03-15 1994-03-08 The United States Of America As Represented By The Department Of Health And Human Services Catalyst for preparing polyacrylamide gel which improves the detection of biomaterials by silver staining
DK0559795T3 (da) * 1990-11-30 1996-01-29 Monoclonetics Int Fremgangsmåder til diagnosticering af kroniske smerter i lænderegionen og halshvrivelsøjlen
US5844097A (en) * 1990-11-30 1998-12-01 Monoclonetics International, Inc. Methods for the diagnosis of peripheral nerve damage
US5378602A (en) * 1991-05-29 1995-01-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Highly informative microsatellite repeat polymorphic DNA markers twenty-[seven]six
US5861504A (en) * 1991-05-29 1999-01-19 The United States Of America As Represented By The Department Of Health And Human Services Eleven highly informative microsatelite repeat polymorphic DNA markers
US5468610A (en) * 1991-05-29 1995-11-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Three highly informative microsatellite repeat polymorphic DNA markers
US5429947A (en) * 1992-06-17 1995-07-04 Merril; Carl R. Diagnosing Alzheimer's disease and schizophrenia
US5811093A (en) * 1994-04-05 1998-09-22 Exponential Biotherapies, Inc. Bacteriophage genotypically modified to delay inactivations by the host defense system
AU699322B2 (en) * 1994-04-05 1998-12-03 Exponential Biotherapies, Inc. Antibacterial therapy with genotypically modified bacteriophage
US20010043924A1 (en) * 1994-04-05 2001-11-22 Exponential Biotherapies, Inc. Antibacterial therapy with bacteriophage physico-chemically altered to delay inactivation by the host defense system
US5736388A (en) * 1994-12-30 1998-04-07 Chada; Sunil Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells
SE506771C2 (sv) * 1996-02-06 1998-02-09 Gotpat 105 Ab Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna
AU3737297A (en) * 1996-08-05 1998-02-25 Brigham And Women's Hospital Bacteriophage-mediated gene therapy
US20020177614A1 (en) * 2001-03-23 2002-11-28 Merril Carl R. Methods for treating nuerodegenerative diseases including alzheimer's
US7521479B2 (en) * 2001-04-16 2009-04-21 Panacea Pharmaceuticals, Inc. Methods of treating prion disease in mammals
US20050118567A1 (en) * 2002-01-23 2005-06-02 Merril Carl R. Method for determining sensitivity to a bacteriophage
US7399753B2 (en) * 2002-02-25 2008-07-15 Virxsys Corporation Trans-splicing mediated photodynamic therapy

Also Published As

Publication number Publication date
ES2252263T3 (es) 2006-05-16
WO2002007742A3 (fr) 2002-08-08
DE60113851T2 (de) 2006-07-20
US7163818B2 (en) 2007-01-16
ATE305793T1 (de) 2005-10-15
CA2417188A1 (fr) 2002-01-31
WO2002007742A9 (fr) 2002-04-18
WO2002007742A2 (fr) 2002-01-31
WO2002007742A8 (fr) 2003-10-30
DE60113851D1 (de) 2006-02-16
EP1305038B1 (fr) 2005-10-05
US20030216338A1 (en) 2003-11-20
EP1305038A2 (fr) 2003-05-02

Similar Documents

Publication Publication Date Title
AU2001278003A1 (en) Bacteriophage having multiple host range
AU2002328972A1 (en) Piperidine derivatives as antibacterial agents
AU2003291227A1 (en) Antibacterial agents
WO2003088897A3 (fr) Inhibiteurs de fab i
SE0102315D0 (sv) Compounds
EP1594444A3 (fr) Methodes et compositions destinees au traitement et a la prevention d'infections a staphylocoque ou autres infections bacteriennes
GB0125222D0 (en) Composition for the treatment of microbial infections
EP3738591A3 (fr) Nouveaux agents antibactériens
WO2003099217A3 (fr) Methodes de traitement d'infections bacteriennes et de maladies associees
AU2003901008A0 (en) Composition for the treatment and prevention of bacterial infections
EP1560821B8 (fr) Agents antibacteriens
EA200600280A1 (ru) Композиции на основе производных липопептидных антибиотиков и способы их применения
AU2005099A (en) Methods and compositions for the treatment and prevention of (staphylococcus aureus) infections
AU2003245928A1 (en) Antibacterial amide macrocycles
AU2002232558A1 (en) Compounds, compositions and methods for treatment of parasitic infections
AU2003294565A1 (en) Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents
BR0307085A (pt) Terapia combinada para o tratamento de infecções bacterianas
WO2004034961A3 (fr) Antimicrobiens et leurs utilisations
NZ509051A (en) Chemotaxis-inhibiting protein of staphylococcus (CHIPS) and its use
AU2001265876A1 (en) Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases
AU2002334761A1 (en) Methods of treating drug-resistant bacterial infections
AU2003259159A1 (en) N-aryl-2-oxazolidinones and their derivatives
WO2002057281A3 (fr) Aminoglycosides utilises comme antibiotiques
AU2002251202A1 (en) Intimins for the prevention or treatment of infections: i
AU2002303480A1 (en) Glycopeptide antibiotics